Arqule (ARQL) Stock News
NASDAQ:ARQL - Nasdaq -
ARQL Latest News, Press Relases and Analysis
Why Biotech Stock ArQule Soared 108% in December
This cancer-drug developer received a buyout offer from a big pharmaceutical company.
Mentions: MRK
Deep Dive: Here are the best-performing Nasdaq stocks of 2019
AMD, Lam Research and KLA top the list.
The best performing Nasdaq stocks of 2019
AMD, Lam Research and KLA top the list.
Company News for Dec 10, 2019
Companies in the news are: ARQL, THOR, CGC, FATE
Deep Dive: Here are the best-performing Nasdaq stocks of 2019
AMD, Lam Research and KLA top the list.
A Perspective On Biopharma's Record M&A Run In 2019
This year was a watershed one for biopharma M&A, with several multibillion-dollar deals announced thus far. M&A activity in 2019 kickstarted with a big deal. Bristol-Myers...
Merck begins tender offer to acquire Arqule
Merck (NYSE:MRK) commences a cash tender offer to purchase all outstanding common shares of ArQule (NASDAQ:ARQL). Upon closing of the tender offer, stockholders of ArQule will receive $20 in cash for
Mentions: MRK
The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week
Biotech stocks were seen consolidating last week after advancing in the previous week. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) reached a 52-week high of 121.16 Monday...
Space Tourism Is Getting Closer. Here’s How Much It Will Cost.
Jeff Bezos’ Blue Origin and Richard Branson’s Virgin Galactic have plans to send tourists into space next year. Elon Musk’s SpaceX is in the hunt too, and a Boeing and Lockheed JV. It won’t be cheap.
Dow Jones Hits Record High On China Trade Deal; Lululemon, Adobe, Tesla, Facebook, Boeing, Chips, Biotechs Make News: Weekly Review
The Dow Jones hit a new high on the China trade deal and other moves to end stock market uncertainty. Adobe, Facebook, Lululemon and Tesla were key movers.
: There’s more upside for biotech even after 24% gains in two months
Seven biotech stocks to consider buying.
Why Merck, Sanofi News Helped This Biotech Rocket 31% Over Two Days
PRNB stock has rocketed 31% this week amid enthusiasm for the biotech company's technology — highlighted by notable moves from Merck and Sanofi.
Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but...
Why Biotech ETFs are Surging to New Highs
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of ArQule, Inc - ARQL
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.